Article Containing Segregated Biguanide and Lewis Acid

• US 20100082097A1
• Filed: 09/30/2009
• Published: 04/01/2010
• Est. Priority Date: 10/01/2008
• Status: Abandoned Application

• Current Assignee: Teleflex Medical Incorporated (Teleflex Incorporated)
• Original Assignee: Teleflex Medical Incorporated (Teleflex Incorporated)
• Inventors: Wang, Perry G., Rosenblatt, Joel, Do, Hiep
• Application Number:
  US12/570,707
• Publication Number:
  US 20100082097A1
• Time in Patent Office: Days
• US Class Current: 623/1.460
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 29/14 Materials characterised by their function or physical properties , e.g. lubricating compositions
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: B29C 48/09 Articles with cross-sections having partially or fully enclosed cavities, e.g. pipes or channels
• CPC Class Codes: B29C 48/151 Coating hollow articles
• CPC Class Codes: B29C 48/152 the inner surfaces thereof
• CPC Class Codes: B29C 48/153 Coating both inner and outer surfaces
• CPC Class Codes: B29C 48/18 the components being layers
• CPC Class Codes: B29L 2009/00 Layered products
• CPC Class Codes: B29L 2031/7542 Catheters

Abstract

A medical device includes a first region having a biguanide or a pharmaceutically acceptable salt thereof and a second region having a Lewis acid.

Claims

1. A medical device comprising:

a first region comprising a biguanide or a pharmaceutically acceptable salt thereof; and

a second region comprising a Lewis acid.

2. The medical device according to claim 1, wherein the biguanide is an Alexidine.

3. The medical device according to claim 1, wherein the biguanide is a chlorhexidine.

4. The medical device according to claim 1, wherein the biguanide is a polyhexamethyl biguanide (PHMB).

5. The medical device according to claim 1, wherein the biguanide includes a mixture of a plurality of biguanide agents.

6. The medical device according to claim 1, wherein the Lewis acid is a triarylmethane.

7. The medical device according to claim 6, wherein the triarylmethane includes brilliant green.

8. The medical device according to claim 6, wherein the Lewis acid includes a methyl violet.

9. The medical device according to claim 8, wherein the methyl violet is gentian violet.

10. The medical device according to claim 1, wherein the Lewis acid is a methyl donor.

11. The medical device according to claim 1, wherein the Lewis acid includes a mixture of a plurality of Lewis acids.

12. The medical device according to claim 1, wherein the first region is a first layer.

13. The medical device according to claim 12, wherein the second region is a second layer.

14. The medical device according to claim 13, wherein the first region and second region are co-extruded.

15. The medical device according to claim 14, further comprising:

a third layer disposed between the first layer and second layer.

16. The medical device according to claim 1, further comprising:

a multitude of first regions encapsulated in the medical device; and

a multitude of second regions encapsulated in the medical device.

17. The medical device according to claim 16, wherein the multitude of first regions and the multitude of second regions are microspheres.

18. The medical device according to claim 1, wherein the first region is a first stripe disposed longitudinally along the medical device.

19. The medical device according to claim 18, wherein the second region is a second stripe disposed longitudinally adjacent to the first stripe.

20. The medical device according to claim 1, wherein the medical device is a catheter, tube, suture, non-woven material, mesh, drain, shunt, or stent.

21. A method of making an infection resistant medical article, the method comprising steps of:

generating a first region comprising a biguanide or a pharmaceutically acceptable salt thereof; and

generating a second region comprising a Lewis acid.

22. The method according to claim 21, further comprising the step of:

selecting an Alexidine as the biguanide.

23. The method according to claim 21, further comprising the step of:

selecting a chlorhexidine as the biguanide.

24. The method according to claim 21, further comprising the step of:

selecting a polyhexamethyl biguanide (PHMB) as the biguanide.

25. The method according to claim 21, further comprising the step of:

selecting a mixture of a plurality of biguanides as the biguanide.

26. The method according to claim 21, further comprising the step of:

selecting a triarylmethane as the Lewis acid.

27. The method according to claim 26, further comprising the step of:

selecting a brilliant green as the triarylmethane.

28. The method according to claim 26, further comprising the step of:

selecting a methyl violet as the Lewis acid.

29. The method according to claim 28, further comprising the step of:

selecting a gentian violet as the methyl violet.

30. The method according to claim 21, further comprising the step of:

selecting a methyl donor as the Lewis acid.

31. The method according to claim 21, further comprising the step of:

selecting a mixture of a plurality of Lewis acids as the Lewis acid.

32. The method according to claim 21, further comprising the step of:

generating a first layer as the first region.

33. The method according to claim 32, further comprising the step of:

generating a second layer as the second region.

34. The method according to claim 33, further comprising the step of:

co-extruding the first region and second region.

35. The method according to claim 34, further comprising the step of:

co-extruding a third layer disposed between the first layer and second layer.

36. The method according to claim 21, further comprising the steps of:

encapsulating a multitude of first regions in the medical device; and

encapsulating a multitude of second regions in the medical device.

37. The method according to claim 36, further comprising the steps of:

generating a first multitude of microspheres including the biguanide; and

generating a second multitude of microspheres including the Lewis acid.

38. The method according to claim 35, further comprising the step of:

co-extruding a first stripe disposed longitudinally along the medical device.

39. The method according to claim 38, further comprising the step of:

co-extruding a second stripe disposed longitudinally adjacent to the first stripe.

40. The method according to claim 21, further comprising the step of:

fabricating a catheter, tube, suture, non-woven material, mesh, drain, shunt, or stent with the first region and second region.

41. A medical device comprising:

a first region comprising a chlorhexidine or a pharmaceutically acceptable salt thereof;

a second region comprising a gentian violet; and

a third region disposed between the first region and the second region to separate the first region from the second region.